Eduardo G Arathoon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5375324/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Doubleâ€Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis. Clinical Infectious Diseases, 2001, 33, 1529-1535.	5.8	292
2	A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. American Journal of Medicine, 2002, 113, 294-299.	1.5	281
3	Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases. Antimicrobial Agents and Chemotherapy, 2002, 46, 451-457.	3.2	255
4	Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrobial Agents and Chemotherapy, 1988, 32, 369-373.	3.2	166
5	A Pan-American 5-Year Study of Fluconazole Therapy for Deep Mycoses in the Immunocompetent Host. Clinical Infectious Diseases, 1992, 14, S68-S76.	5.8	128
6	Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients. Clinical Infectious Diseases, 2006, 42, 273-280.	5.8	98
7	Treatment of Mycoses with Itraconazole. Annals of the New York Academy of Sciences, 1988, 544, 451-470.	3.8	96
8	Initial Experience in Therapy for Progressive Mycoses with Itraconazole, the First Clinically Studied Triazole. Clinical Infectious Diseases, 1987, 9, S77-S86.	5.8	84
9	Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations. Journal of the American Academy of Dermatology, 1990, 23, 593-601.	1.2	83
10	Local Population Structure and Patterns of Western Hemisphere Dispersal for <i>Coccidioides</i> spp., the Fungal Cause of Valley Fever. MBio, 2016, 7, e00550-16.	4.1	71
11	Coccidioidomycosis in Latin America. Medical Mycology, 2019, 57, S46-S55.	0.7	68
12	Safety Evaluation of Chronic Fluconazole Therapy. Chemotherapy, 1997, 43, 371-377.	1.6	59
13	Infections due to achromobacter xylosoxidans. Case report and review of the literature. Infection, 1986, 14, 279-282.	4.7	55
14	Development and Evaluation of an Enzyme-Linked Immunosorbent Assay To Detect <i>Histoplasma capsulatum</i> Antigenuria in Immunocompromised Patients. Vaccine Journal, 2009, 16, 852-858.	3.1	53
15	Increased risk of miscarriage among women experiencing physical or sexual intimate partner violence during pregnancy in Guatemala City, Guatemala: cross-sectional study. BMC Pregnancy and Childbirth, 2011, 11, 49.	2.4	53
16	The Epidemiologic Patterns of Drug-resistant <i>Mycobacterium tuberculosis</i> Infections: A Community-based Study. The American Review of Respiratory Disease, 1989, 139, 1282-1285.	2.9	51
17	Clinical efficacy of echinocandin antifungals. Current Opinion in Infectious Diseases, 2001, 14, 685-691.	3.1	48
18	Epidemic gram-negative bacteremia in a neonatal intensive care unit in Guatemala. American Journal of Infection Control, 1994, 22, 163-171.	2.3	44

#	Article	IF	CITATIONS
19	High Mortality and Coinfection in a Prospective Cohort of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients with Histoplasmosis in Guatemala. American Journal of Tropical Medicine and Hygiene, 2017, 97, 42-48.	1.4	42
20	Disseminated histoplasmosis in Central and South America, the invisible elephant. Aids, 2016, 30, 167-170.	2.2	40
21	Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates. Antimicrobial Agents and Chemotherapy, 1990, 34, 1655-1659.	3.2	30
22	Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Aids, 2000, 14, 1973-1978.	2.2	30
23	Effect of Darunavir on Lipid Profile in HIV-Infected Patients. HIV Clinical Trials, 2012, 13, 256-270.	2.0	29
24	Burden of serious fungal infections in Guatemala. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 965-969.	2.9	26
25	The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. Open Forum Infectious Diseases, 2020, 7, ofz534.	0.9	24
26	Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. Aids, 2020, 34, 1625-1632.	2.2	23
27	The Fight against HIV-Associated Disseminated Histoplasmosis in the Americas: Unfolding the Different Stories of Four Centers. Journal of Fungi (Basel, Switzerland), 2019, 5, 51.	3.5	22
28	A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala. Journal of Fungi (Basel, Switzerland), 2021, 7, 268.	3.5	22
29	Prosthetic Hip Infection Caused by Listeria monocytogenes. Journal of Infectious Diseases, 1988, 157, 1282-1283.	4.0	20
30	Availability of HIV Care in Central America. JAMA - Journal of the American Medical Association, 2001, 286, 853.	7.4	18
31	Cryptococcal osteomyelitis of the skull. Medical Mycology, 2011, 49, 1-5.	0.7	18
32	Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. International Journal of STD and AIDS, 2013, 24, 12-17.	1.1	18
33	Whole genome sequencing identifies circulating Beijing-lineage Mycobacterium tuberculosis strains in Guatemala and an associated urban outbreak. Tuberculosis, 2015, 95, 810-816.	1.9	16
34	Impact of the COVID-19 pandemic on HIV care in Guatemala. International Journal of Infectious Diseases, 2021, 108, 422-427.	3.3	16
35	Efficacy of Itraconazole in Blastomycosis in a Murine Model and Comparison with Ketoconazole. Mycoses, 1989, 32, 109-112.	4.0	14
36	Adherence to Antiretroviral Therapy in an Urban, Free-Care HIV Clinic in Guatemala City, Guatemala. Journal of the International Association of Providers of AIDS Care, 2010, 9, 390-395.	1.2	14

#	Article	IF	CITATIONS
37	Seroprevalence of HIV, Hepatitis B, and Syphilis Among Pregnant Women at the General Hospital, Guatemala City, 2005-2009. Journal of the International Association of Providers of AIDS Care, 2010, 9, 313-317.	1.2	13
38	Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality. Microorganisms, 2021, 9, 2596.	3.6	13
39	A cross-sectional study of risk factors for HIV among pregnant women in Guatemala City, Guatemala: lessons for prevention. International Journal of STD and AIDS, 2010, 21, 789-796.	1.1	10
40	Does HIV VCT Reduce Risk Behaviors? An Observational Study in Guatemala City. Current HIV Research, 2010, 8, 121-126.	0.5	8
41	Nosocomial Infection Due to Vibrio cholerae in Two Referral Hospitals in Guatemala. Infection Control and Hospital Epidemiology, 1996, 17, 371-372.	1.8	7
42	Diagnosis of fungal opportunistic infections in people living with HIV from Guatemala and El Salvador. Mycoses, 2021, 64, 1563-1570.	4.0	6
43	The emergence of AIDS in Guatemala: inpatient experience at the Hospital General San Juan de Dios. International Journal of STD and AIDS, 2003, 14, 810-813.	1.1	4
44	The MANGUA Project: A Population-Based HIV Cohort in Guatemala. AIDS Research and Treatment, 2015, 2015, 1-8.	0.7	4
45	Experience of a pediatric HIV clinic in Guatemala City. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2009, 25, 51-55.	1.1	4
46	Serum HIV-1 p24 levels and body weight measurements before and after 4 weeks of diethylcarbamazine treatment given to HIV-1 seropositive persons. International Journal of Antimicrobial Agents, 1994, 3, 275-278.	2.5	3
47	Atypical Infection Due to Vibrio cholerae in Patients Infected With Human Immunodeficiency Virus. Clinical Infectious Diseases, 1995, 21, 1516-1517.	5.8	3
48	Is Expanded HIV Testing Associated with Earlier HIV Diagnosis? Results from an HIV Clinic in Guatemala City. Journal of the International Association of Providers of AIDS Care, 2016, 15, 201-204.	1.5	3
49	Epidemiology and Mortality of Cryptococcal Disease in Guatemala: Two-Year Results of a Cryptococcal Antigen Screening Program. Microorganisms, 2022, 10, 1388.	3.6	3
50	Can a clinical prediction tool guide HIV-testing decisions? Experience at a national hospital in Guatemala. International Journal of STD and AIDS, 2009, 20, 30-34.	1.1	2
51	Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults. Journal of the International AIDS Society, 2014, 17, 19783.	3.0	2
52	Annotated Genome Sequences of 16 Lineage 4 Mycobacterium tuberculosis Strains from Guatemala. Genome Announcements, 2018, 6, .	0.8	2
53	Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE Open Medicine, 2017, 5, 205031211668648.	1.8	1
54	Characterization of the Proportion of Clustered Tuberculosis Cases in Guatemala: Insights from a Molecular Epidemiology Study, 2010–2014. American Journal of Tropical Medicine and Hygiene, 2022, 106, 1173-1181.	1.4	1

#	Article	IF	CITATIONS
55	Use of patient-delivered coupons as a vehicle for HIV partner notification: Results of a pilot study in Guatemala. Preventive Medicine, 2010, 51, 443-444.	3.4	0
56	Histoplasmosis, Blastomycosis, Coccidioidomycosis, and Cryptococcosis. , 2011, , 573-581.		0
57	Vitamin D Status in Children Living with HIV on Highly Active Antiretroviral Therapy. Current Tropical Medicine Reports, 2017, 4, 158-165.	3.7	0